Business
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for t...
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) ...